Anti-Sp1 approaches, such as transcriptional inhibitors or microRNA-based therapies targeting miR-382, a tumor suppressor gene, have demonstrated efficacy in preclinical models by suppressing tumor growth and metastasis. This evidence concerns the gene SP1 and neoplasm.